Search This Blog

Wednesday, May 8, 2019

Adverum Biotechnologies reports Q1 EPS (23c), consensus (27c)

Revenue, consisting of revenue from collaborative research, was $0.0 million the three months ended March 31, 2019, compared to $0.2 million for the same period in 2018. Revenue decreased as no research activities were performed under collaboration agreements for the three month period in 2019. Cash, cash equivalents and short-term investments were $189.5 million as of March 31, 2019, compared to $205.1 million as of December 31, 2018. Adverum expects this quarter-end cash position to fund operations into 2021.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.